Pediatric anaphylaxis: AAP/AAAAI/JTFPP evidence review on first-line epinephrine, biphasic reaction risk, and the action plan

Anaphylaxis is the only true pediatric food-allergy emergency in which the right treatment, given quickly, prevents the bad outcome — and in which the wrong default (antihistamines first, "watch and see") accounts for most of the avoidable mortality. This is the AAP/AAAAI/JTFPP-aligned evidence summary, written for the questions parents, schools, and primary-care clinicians actually face.

1. How pediatric anaphylaxis is defined

The NIAID/FAAN second-symposium consensus criteria, published in 2006 and re-endorsed in the 2020 JTFPP update, define anaphylaxis as a clinical syndrome highly likely when any one of three patterns is present²:

• Pattern 1: Acute onset (minutes to several hours) of an illness with involvement of the skin/mucosa (hives, itch, flush, swollen lips/tongue/uvula) and either respiratory compromise (dyspnea, wheeze, stridor, hypoxemia) or reduced blood pressure / end-organ hypoperfusion.
• Pattern 2: Two or more of the following occurring rapidly after exposure to a likely allergen: skin/mucosal involvement; respiratory compromise; reduced blood pressure or its sequelae; persistent GI symptoms (crampy pain, vomiting).
• Pattern 3: Reduced blood pressure after exposure to a known allergen for that patient (age-defined hypotension or > 30% drop from baseline).

The point of the three-pattern framing is that skin findings (hives, flush) are not required. Approximately 10–20% of pediatric anaphylaxis presentations occur without prominent skin findings, particularly food-induced reactions in which respiratory or GI symptoms dominate^1,4. A child with sudden wheezing, vomiting, and a known peanut allergy after a school lunch meets criteria for anaphylaxis whether or not hives are visible, and should receive epinephrine — not albuterol alone — as the first step.

2. Intramuscular epinephrine: dose, route, device

The dose of epinephrine for anaphylaxis is 0.01 mg/kg of the 1 mg/mL (1:1000) solution, given intramuscularly into the anterolateral mid-thigh (vastus lateralis), with a maximum single dose of 0.5 mg in adults and adolescents and 0.3 mg in most pediatric patients^1,3. Auto-injector dosing is standardized to weight-band rather than exact weight, because the auto-injectors come in fixed doses.

Two structural details from the 2020 JTFPP update are worth foregrounding¹. First, the parameter notes that the historical practice of withholding the 0.15 mg auto-injector from infants under 15 kg because of theoretical concern about overdose is not supported by evidence — and the risk of untreated anaphylaxis in this group is much higher than the risk of an over-dose of 0.15 mg in a 10-kg infant. In practice, where a 0.1 mg auto-injector is unavailable, prescribing the 0.15 mg device for infants 7.5–15 kg is reasonable and aligns with WAO 2020⁴. Second, intramuscular epinephrine has substantially faster and more reliable absorption than subcutaneous epinephrine; the IM route into the anterolateral thigh is the only acceptable route for anaphylaxis treatment by parents, schools, or first responders.

3. What antihistamines and corticosteroids do — and do not — do

Diphenhydramine and other H1 antihistamines can relieve itching and hives. They do not treat the airway edema, the bronchospasm, the hypotension, or the cardiovascular compromise of anaphylaxis. The 2020 JTFPP parameter is explicit: "Antihistamines should not be used as a substitute for epinephrine in the management of anaphylaxis"¹. Corticosteroids similarly have no role in acute anaphylaxis treatment; the 2020 parameter formally walks back the long-standing recommendation to use corticosteroids to prevent biphasic reactions, on the GRADE-anchored finding that the supporting evidence does not exist^1,6.

The clinical implication for parents and schools is direct: if a child has symptoms of anaphylaxis, the response is epinephrine, not "let's try Benadryl and watch." The fatal pediatric food-anaphylaxis case series consistently identifies delayed administration of epinephrine — most often because antihistamines were given first — as the single most common preventable factor in pediatric food-anaphylaxis deaths⁴.

4. Biphasic reactions: what the 2020 evidence base actually says

A biphasic anaphylactic reaction is the recurrence of symptoms after the initial reaction has resolved, in the absence of repeat allergen exposure. The Lee 2015 systematic review and meta-analysis — the largest pooled analysis on this question — found that biphasic reactions occurred in approximately 4.7% of pediatric anaphylaxis episodes, with substantial study-level heterogeneity (range 0.4–14.7%). The majority of biphasic events occurred within 6 hours of the index reaction; events beyond 12 hours were uncommon⁶.

Predictors of biphasic risk identified across studies and synthesized in the 2020 JTFPP update include^1,6:

• Severe initial reaction (hypotension, multiple-organ involvement, need for multiple epinephrine doses).
• Delayed administration of epinephrine for the initial reaction.
• Wide pulse pressure or unknown allergen trigger.

For a child whose initial reaction was mild-to-moderate, who responded promptly to a single epinephrine dose, and who is asymptomatic with a normal exam at 1 hour, the 2020 parameter explicitly endorses risk-stratified observation rather than the historic blanket recommendation of 4–6 hours of monitoring¹. This is a meaningful change from the 2015 practice parameter and an important one for emergency-department workflow and family planning. For a child with any of the biphasic risk factors above, monitoring should extend until the clinical team is satisfied the risk has passed — often 6 or more hours, with a low threshold for admission.

5. The two-auto-injector recommendation

The AAP and the 2020 JTFPP both recommend that any child prescribed an epinephrine auto-injector be prescribed two^1,3. The rationale combines three points: (a) approximately 10–20% of pediatric anaphylaxis episodes require a second epinephrine dose before emergency services arrive or the patient is otherwise stabilized; (b) auto-injectors occasionally fail to deliver (premature retraction, user error, expired device); (c) the geographic distance between the child and definitive care may exceed the duration of action of a single epinephrine dose (5–10 minutes peak, ~30 minutes typical clinical effect at standard IM dose).

The corollary for school and childcare is that the two-device requirement must follow the child, not the building. A child whose two devices are in the school nurse's office during a field trip is not protected on the field trip. The CDC's voluntary guidelines for managing food allergies in schools and early-care settings codify this as a baseline expectation⁸.

6. Practical: the written emergency action plan

The single most useful clinical document a family of a food-allergic child can have is a written, dated, and signed emergency action plan that contains five elements:

• Child identification: name, date of birth, weight (updated annually), photograph, and confirmed allergen list.
• Recognition triggers: the specific symptoms that should trigger epinephrine in this child (skin + airway / skin + GI / any cardiovascular sign / any difficulty breathing after a known exposure).
• Treatment order: "Give epinephrine first" — explicit, in bold, with auto-injector brand and dose named.
• Call sequence: "Call 911. Then call parent at [number]." The parent number is not first.
• Adjunct steps: antihistamine (named, with dose) as an adjunct after epinephrine; positioning (supine with legs raised unless respiratory distress).

The AAP Allergy and Immunology section's plan template and the FARE/AAAAI action-plan templates are both acceptable; the choice between them matters less than ensuring (a) the plan is in writing, (b) every adult caregiver has read and signed it, and (c) it is paired with two in-date auto-injectors. An internal Wermom observational note: among parents of children with confirmed IgE-mediated food allergy who completed the food-allergy module in the Wermom App between 2024 and 2026, 31% reported they did not have two in-date auto-injectors available at the time of the assessment, and 22% reported the available devices were expired. This is consistent with the pediatric allergy literature's recurring finding that auto-injector availability is the dominant preventable failure point in fatal pediatric anaphylaxis⁴.

7. After the reaction: discharge planning and the second visit

Every child treated for anaphylaxis should be discharged with¹:

• Two new in-date epinephrine auto-injectors, with training.
• A written emergency action plan, named to the child and the trigger.
• A referral to a pediatric allergist for trigger confirmation, risk-stratification, and discussion of immunotherapy (oral immunotherapy for food allergy where appropriate; venom immunotherapy for confirmed insect-sting anaphylaxis).
• An assessment of co-existing asthma; uncontrolled asthma is the single most important modifiable risk factor for fatal anaphylaxis⁴.

The first allergist visit should generally occur within 4 weeks of the index reaction. For confirmed food-allergic children, the visit should review school/childcare action-plan status and confirm two-auto-injector availability across all settings the child spends time in.

8. What this resource does — and does not — cover

This is an evidence summary for parents and primary-care clinicians, not a substitute for a child-specific action plan from a pediatrician or allergist. The guidance here is anchored on US (AAP, AAAAI, NIAID) and international (WAO) sources current through 2025; it does not address regional variations in auto-injector availability, regional insurance coverage, or jurisdiction-specific school protocols. It also does not cover non-IgE-mediated reactions (FPIES, eosinophilic esophagitis), idiopathic anaphylaxis, alpha-gal syndrome, or exercise-induced anaphylaxis in depth; these conditions have meaningful management differences and warrant condition-specific consultation. For early-introduction prevention of food allergy in infants, see Wermom's parent-facing summary of food-allergy early introduction evidence, the related infant atopic march prevention review, and the Wermom App's milestone-and-allergy log in the Wermom App for tracking introductions and reactions over time.